• PDF / 141,443 Bytes
• 1 Pages / 623.591 x 841.847 pts Page_size
• 51 Downloads / 158 Views

DOWNLOAD

REPORT

---

1

S

Secondary parotid mucoepidermoid cancer in a patient who had received radiotherapy: case report At 15 years of age, a patient presented with M3 acute promyelocytic leukaemia (APML). He received chemotherapy according to the AML 10 protocol, and achieved complete remission. However, 18 months after his diagnosis, a relapse occurred and he received further reinduction and consolidation chemotherapy, followed by cyclophosphamide 200 mg/kg [frequency of administration and duration of treatment not stated] and total body irradiation (12 Gy in 6 fractions) before stem cell rescue; he received etoposide during both initial and relapse treatment [dosages and duration of treatments not stated].* Seven years after bone marrow transplantation, he developed a 5 × 5 cm parotid mucoepidermoid cancer. He received local radiotherapy and, at follow-up after 3 years, he was in remission. Author comment: "Our patient received cyclophosphamide and etoposide. These agents are associated with secondary leukaemias and secondary bladder cancer (cyclophosphamide). . . It is not known whether the addition of chemotherapy further increases the risk of radiotherapy-induced malignancies." * It was confirmed by personal communication with the author that the patient received etoposide during both initial and relapse treatment. Piccinelli KJ, et al. Secondary parotid mucoepidermoid carcinoma after TBI and chemotherapy in childhood AML. Pediatric Blood and Cancer 47: 345-346, No. 3, 801046041 Sep 2006 - England

0114-9954/10/1123-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Reactions 14 Oct 2006 No. 1123